Antithrombotic Effect of Antisense Factor XI Oligonucleotide Treatment in Primates

Abstract

These results indicate that reducing FXI levels using antisense oligonucleotides is a promising alternative to direct FXI inhibition, and that targeting FXI may be potentially safer than conventional antithrombotic therapies that can markedly impair primary hemostasis.